[
    [
        {
            "time": "2018-10-15",
            "original_text": "Here’s What Hedge Funds Think About Eli Lilly and Company (LLY)",
            "features": {
                "keywords": [
                    "Hedge Funds",
                    "Eli Lilly",
                    "LLY"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Here’s What Hedge Funds Think About Eli Lilly and Company (LLY)",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-16",
            "original_text": "3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates",
            "features": {
                "keywords": [
                    "Drug",
                    "Biotech",
                    "Q3 Earnings",
                    "Estimates"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-17",
            "original_text": "J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector",
            "features": {
                "keywords": [
                    "J&J",
                    "JNJ",
                    "Q3 Earnings",
                    "Pharma Sector"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-18",
            "original_text": "Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study",
            "features": {
                "keywords": [
                    "Dermira",
                    "Lebrikizumab",
                    "Eczema",
                    "Late-Stage Study"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]